Firm’s lead RNAi therapeutic is in Phase II development.

Alnylam Pharmaceuticals and Kyowa Hakko Kogyo forged an exclusive alliance to develop and commercialize ALN-RSV01 in Japan and other major markets in Asia. ALN-RSV01 is Alnylam’s lead RNAi therapeutic, which is in Phase II development for the treatment of respiratory syncytial virus infection.

Kyowa Hakko will pay Alnylam $15 million upfront and up to an additional $78 million in development and sales milestone payments. Upon commercialization, Alnylam will receive double-digit royalties from Kyowa Hakko based on the sales of ALN-RSV01 in this territory. The partnership also includes additional RSV-specific RNAi therapeutic compounds that comprise the ALN-RSV program. Alnylam retains all development and commercialization rights worldwide, excluding Asia.


Related Links:


RNAi Researchers Galvanized by Advances


RNAi Technologies Become Discovery Staple


Multidisciplinary Approach to RNAi

Previous articleVitamin D Linked to Colon Cancer Survival
Next articleBIO Exclusive: Former FDA Officials Articulate their Vision for a Stronger FDA